BeiGene Ltd. (BGNE) Director Buys $960,000.00 in Stock
BeiGene Ltd. (NASDAQ:BGNE) Director Thomas Malley purchased 30,000 shares of BeiGene stock in a transaction dated Wednesday, November 23rd. The stock was bought at an average cost of $32.00 per share, for a total transaction of $960,000.00. Following the completion of the purchase, the director now directly owns 30,000 shares in the company, valued at approximately $960,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of BeiGene Ltd. (NASDAQ:BGNE) traded down 4.72% during midday trading on Monday, reaching $30.88. 113,072 shares of the company traded hands. The company’s 50 day moving average is $0.00 and its 200-day moving average is $0.00. BeiGene Ltd. has a 12 month low of $22.51 and a 12 month high of $37.89.
BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($1.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.30. Equities analysts anticipate that BeiGene Ltd. will post ($3.96) EPS for the current year.
A number of large investors have recently modified their holdings of BGNE. Credit Suisse AG boosted its stake in BeiGene by 9.1% in the third quarter. Credit Suisse AG now owns 12,000 shares of the company’s stock valued at $370,000 after buying an additional 1,000 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in BeiGene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock valued at $191,000 after buying an additional 2,589 shares in the last quarter. BlackRock Inc. boosted its stake in BeiGene by 3,410.1% in the second quarter. BlackRock Inc. now owns 3,826 shares of the company’s stock valued at $114,000 after buying an additional 3,717 shares in the last quarter. Bank of Montreal Can purchased a new stake in BeiGene during the second quarter valued at about $191,000. Finally, Brown Advisory Inc. boosted its stake in BeiGene by 13.1% in the second quarter. Brown Advisory Inc. now owns 112,744 shares of the company’s stock valued at $3,360,000 after buying an additional 13,092 shares in the last quarter. 32.25% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently issued reports on BGNE. Zacks Investment Research raised shares of BeiGene from a “sell” rating to a “hold” rating in a research note on Tuesday, October 11th. Maxim Group set a $41.00 price target on shares of BeiGene and gave the company a “buy” rating in a research note on Saturday, October 8th. Finally, Cowen and Company reissued a “buy” rating on shares of BeiGene in a research note on Friday, October 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $40.00.
BeiGene Company Profile
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.